Aurobindo gets USFDA nod for cholesterol drug

Aurobindo Pharma today announced that it has received tentative approval for Resuvastatin Calclum tablets - 5mg, 10mg, 20mg and 40mg - from the Unites States Food and Drug Administration (USFDA).

Resuvastatin Calclum tablets are indicated for the treatment of high LDL cholesterol, total cholesterol and falls under cardio vascular (CVS) therapeutic category.

The tablets are generic equivalent of IPR Pharmaceutical Inc's Crestor tablets.

The product has a market size of nearly $2.9 billion for the twelve-month ending December 2009.

Aurobindo has a total of 116 abbreviated new drug application (ANDA) approvals from the USFDA.

In today's trade, the stock closed at Rs895.60, up by 2.38%, with a volume of 8220 shares on the BSE.